Articles

The Next Big Theme: January 2023

Jan 20, 2023

Metaverse & Video Games

Virtual Reality Immerses Itself in 2023

Meta Platforms will allocate an estimated 20% of its overall costs and expenses in 2023 to Reality Labs, its virtual reality (VR) and augmented reality (AR) and Metaverse business.1 In Q3 2022, Meta allocated 18% of its spending to Reality Labs.2 The increased investment reflects the company’s commitment to developing immersive technologies despite the economic downturn and market volatility that hit big tech particularly hard in 2022. This approach is in line with the rapid innovation seen in the VR and AR space at CES 2023. Many companies debuted exciting new products that push boundaries, including Sony PlayStation’s VR2 gaming headset, HTC’s Vive XR Elite headset, and Lumus’ Z-lens technology.

Artificial Intelligence & Cloud Computing

ChatGPT Enters the Cloud

Microsoft is looking to invest $10 billion into OpenAI, which would value the emerging leader in artificial intelligence at $29 billion.3 The deal includes a provision for Microsoft to acquire a 75% share of OpenAI’s profits until the investment is recouped, and ultimately, a 49% stake in the company.4 This move is seen as a strategic one for Microsoft, as the integration of OpenAI’s technology, particularly the natural language processing model ChatGPT, could enhance the company’s search engine capabilities and challenge the dominance of market leader Google. Additionally, Microsoft is expanding its partnership with OpenAI by making their Azure OpenAI Service available to the public, enabling Azure cloud customers to use OpenAI tools for cloud applications such as Dall-E AI art generation and the GPT-3.5 language system, and even plans to add access to ChatGPT in the near future.

Electric Vehicles

Government Pumps in Billions for a Cleaner America

The U.S. Department of Energy recently secured a significant $2.5 billion loan to Ultium to support the construction of large-scale electric vehicle (EV) lithium-ion battery cell manufacturing plants.5 This venture is a collaboration between General Motors and LG-Energy Solution and will involve the construction of state-of-the-art facilities in Ohio, Tennessee, and Michigan, with the possibility of a fourth site in Indiana. The Michigan facility alone is projected to open as early as 2024 and is a key step towards President Biden’s goal of achieving 50% of U.S. auto production to be electric or plug-in hybrid electric vehicles by 2030.6 The commitment to clean transportation extends to the state level, with the California Energy Commission approving a substantial $2.9 billion investment plan to expedite the state’s goals for electric vehicle charging by 2025.7 This funding will support the roll-out of thousands of zero-emission trucks, school buses, and transit buses, and is projected to result in the installation of 90,000 EV chargers across the state – significantly surpassing the current number of 80,000.8 Combined with additional funding from utility companies and other programs, these investments are expected to play a pivotal role in California reaching its goal of deploying 250,000 EV chargers by 2025.

Genomics & Aging Population

COVID-19 Victory: Moderna Takes on Cancer

Utilizing the same messenger RNA technology that made their COVID-19 vaccines successful, Moderna created an experimental cancer vaccine that shows promising results in the treatment of melanoma. In a mid-stage trial, the combination of Moderna’s personalized cancer vaccine and Merck & Co.’s highly effective immunotherapy Keytruda resulted in a 44% reduction in the risk of recurrence or death, compared to Keytruda alone.9

Eli Lilly’s 2023 Biopharma Breakthrough

Eli Lilly is poised for a transformative year as it sets out ambitious plans to submit regulatory applications for five innovative products, launch six phase three trials, and unveil data from six other phase 3 trials.10 These efforts along with diabetes treatment Mounjaro are expected to generate over $30 billion in sales in 2023.11 Regulatory submissions in the U.S., Europe, and Japan include Empagliflozin for chronic kidney disease and donanemab for early Alzheimer’s disease. Lilly also plans to submit tirzepatide for obesity in the U.S. and Europe and lebrikizumab for atopic dermatitis in Japan, further solidifying its position as a leader in pharmaceutical innovation.

Solar Energy & Clean Technology

Solar Energy Achieves Record Conversion Efficiency

JinkoSolar, a leading solar module manufacturer, announced a significant development in its N-type monocrystalline silicon tunnel oxide passivated contact (TOPCon) solar cell technology. The company achieved a maximum solar conversion efficiency of 26.4%, surpassing its previous record of 26.1% set in October.12 The company used advanced techniques such as bulk defect passivation technology, a novel structure polysilicon contact, and metal-silicon interface recombination restraint technology.  Additionally, Canadian Solar announced that its majority-owned subsidiary, CSI Solar Co. Ltd., will begin mass-producing high-efficiency N-type TOPCon solar modules with a power output of up to 690 watts in Q1 2023.13

Internet of Things

Semiconductors in it For the Long Haul

The global market for semiconductor manufacturing equipment is on track to reach a new peak in 2022, with original equipment manufacturers forecasting sales of $108.5 billion, a 6% increase from the previous record of $102.5 billion set in 2021.14 This marks three consecutive years of record revenue for the industry. However, the market is expected to experience a temporary dip in 2023, contracting to $91.2 billion, before rebounding in 2024 due to strong demand in both front-end and back-end segments.15 Additionally, the semiconductor ecosystem is experiencing a surge in growth, as companies leverage funding from the CHIPS Act to drive innovation and production, resulting in over 40 new projects, nearly $200 billion in private investments across 16 states, and the creation of 40,000 new jobs in the industry.16

THE NUMBERS

The following charts examine returns and sales growth expectations by theme, based on their corresponding ETFs.

INTRO TO THEMATIC INVESTING COURSE – ELIGIBLE FOR CE CREDIT

Global X has developed an interactive, self-guided Intro to Thematic Investing course, that is designed to share the latest ideas and best practices for incorporating thematic investing into a portfolio.

This program has been accepted for 1.0 hour of CE credit towards the CFP®, CIMA®, CIMC®, CPWA® or RMA certifications. To receive credit, course takers must submit accurate and complete information on the requested forms, complete the entire course, and receive a 70% or higher on the Intro to Thematic Investing Quiz.

For Canadian course takers: This program has been reviewed by FP Canada and qualifies for 1 FP Canada-Approved CE Credit, in the category of Product Knowledge, towards the CFP® certification or QAFP™ certification. To receive credit, course takers must submit accurate and complete information (including Job Title) on the requested forms, complete the entire course, and receive a 70% or higher on the Intro to Thematic Investing Quiz.

Questions on receiving CE credit may be sent to: Education@globalxetfs.com

KEEP UP WITH THE LATEST RESEARCH FROM GLOBAL X

To learn more about the disruptive themes changing our world, read the latest research from Global X, including:

ETF HOLDINGS AND PERFORMANCE:

To see individual ETF holdings and current performance across the Global X Thematic Growth Suite, including information on the indexes shown, click the below links:

Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Narrowly focused investments may be subject to higher volatility. The funds are non-diversified.

The companies in which the Disruptive Technology Funds invest may be subject to rapid changes in technology, intense competition, rapid obsolescence of products and services, loss of intellectual property protections, evolving industry standards and frequent new product productions, and changes in business cycles and government regulation. There are additional risks associated with investing in mining industries.

The Genomics, Healthcare, Pharmaceutical, Medical Device and Biotechnology sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights.

The value of securities issued by companies in the energy sector may decline for many reasons, including, without limitation, changes in energy prices; international politics; energy conservation; the success of exploration projects; natural disasters or other catastrophes; changes in exchange rates, interest rates, or economic conditions; changes in demand for energy products and services; and tax and other government regulatory policies.

Carefully consider the Funds’ investment objectives, risk factors, charges, and expenses before investing. This and additional information can be found in the Funds’ summary or full prospectus, which may be obtained by calling 1.888.493.8631, or by visiting globalxetfs.com. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times.

Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index. This information is not intended to be individual or personalized investment or tax advice and should not be used for trading purposes. Please consult a financial advisor or tax professional for more information regarding your investment and/or tax situation.